{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-250816","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.932546+00:00","generated_at":"2026-06-10T04:50:34.058594+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Vaxcyte and Sutro finalize Form Definitive Agreement; amend license terms","bullets":["On Sep 28, 2023, Vaxcyte and Sutro mutually agreed on the Form Definitive Agreement to become effective if Vaxcyte exercises the option to source extract.","Concurrently, the companies entered the 2023 Amendment to the Sutro License Agreement, modifying royalty reductions, IP prosecution, and royalty payment reporting.","The previously agreed $5.0M cash payment to Sutro remains due within five business days after mutual agreement on the Form Definitive Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-250816","json":"https://secwatch.observer/filing/0001193125-23-250816.json","markdown":"https://secwatch.observer/filing/0001193125-23-250816.md","text":"https://secwatch.observer/filing/0001193125-23-250816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/0001193125-23-250816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/d548055d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:50:34.058594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b896b3c9cb1c3e1cb92d8b0ac122a76c969e798b","claim":"Vaxcyte, Inc. amended 2023 Amendment with Sutro Biopharma, Inc. (effective 2023-09-28).","evidence_excerpt":"Concurrent with the Companies’ mutual agreement upon the Form Definitive Agreement on September 28, 2023, the Companies entered into the 2023 Amendment.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000119312523250816/0001193125-23-250816-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Sutro Biopharma, Inc."},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}